Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a Trial to Evaluate the Safety, Tolerability, and Efficacy of 12 Weeks of Sovaprevir, ACH-0143102 and Ribavirin in Treatment-Naive Subjects With Chronic Hepatitis C Genotype-1 Viral Infection

Trial Profile

A Phase 2a Trial to Evaluate the Safety, Tolerability, and Efficacy of 12 Weeks of Sovaprevir, ACH-0143102 and Ribavirin in Treatment-Naive Subjects With Chronic Hepatitis C Genotype-1 Viral Infection

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 02 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Odalasvir (Primary) ; Sovaprevir (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Achillion Pharmaceuticals; Alexion Pharmaceuticals
  • Most Recent Events

    • 10 Jul 2014 Status changed from active, no longer recruiting to completed as reported by Clinicaltrials.gov record.
    • 10 Jun 2014 According to an Achillion pharmaceuticals media release, the US FDA removed clinical hold on therapeutic trials with sovaprevir 200 mg in HCV patients and single dose healthy volunteer trials. But maintained a partial hold on multiple dose studies.
    • 14 Mar 2014 Results were presented at the 23rd Asian Pacific Association for the Study of the Liver (APASL) Conference 2014 according to an Achillion Pharmaceuticals media release. Results were also summarised in the media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top